254 related articles for article (PubMed ID: 26039122)
1. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
He J; Shen J; Yang C; Jiang L; Liang W; Shi X; Xu X; He J
Medicine (Baltimore); 2015 Jun; 94(22):e903. PubMed ID: 26039122
[TBL] [Abstract][Full Text] [Related]
2. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
5. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
Hamada C; Tanaka F; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
J Clin Oncol; 2005 Aug; 23(22):4999-5006. PubMed ID: 16051951
[TBL] [Abstract][Full Text] [Related]
7. Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Liang SK; Wu CW; Chang CI; Keng LT; Lee MR; Wang JY; Ko JC; Liao WY; Chen KY; Ho CC; Shih JY; Yu CJ
Cancer Med; 2023 Sep; 12(17):17993-18004. PubMed ID: 37559409
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for resected non-small-cell lung cancer.
Solomon B; Mitchell JD; Bunn PA
Oncology (Williston Park); 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705. PubMed ID: 16425522
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy for non-small cell lung cancer].
Okamoto T; Ichinose Y
Gan To Kagaku Ryoho; 2006 Dec; 33(13):1985-90. PubMed ID: 17197740
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
12. [Postoperative adjuvant chemotherapy for non-small cell lung cancer].
Okamoto T; Ichinose Y
Gan To Kagaku Ryoho; 2005 Jun; 32(6):765-9. PubMed ID: 15984513
[TBL] [Abstract][Full Text] [Related]
13. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
[TBL] [Abstract][Full Text] [Related]
14. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
Tanaka F; Wada H
Gan To Kagaku Ryoho; 2006 Mar; 33(3):300-6. PubMed ID: 16531708
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
18. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Tsuboi M; Ohira T; Saji H; Miyajima K; Kajiwara N; Uchida O; Usuda J; Kato H
Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):73-7. PubMed ID: 17505412
[TBL] [Abstract][Full Text] [Related]
19. Is adjuvant chemotherapy for completely resected p-stage IA (>2 cm) and stage IB non-small-cell lung cancer beneficial for elderly patients? A large, retrospective cohort study based on real-world data from Japan.
Adachi H; Saito A; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H; Japanese Joint Committee Of Lung Cancer Registry
Jpn J Clin Oncol; 2023 Dec; 53(12):1191-1200. PubMed ID: 37626449
[TBL] [Abstract][Full Text] [Related]
20. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
